Ariceum Therapeutics GmbH

Ariceum Therapeutics is a private company focused on developing novel targeted radiopharmaceuticals for the treatment of cancer

Our lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours, which currently have few treatment options and a poor prognosis.

Our second more advanced therapeutic product, ATT001 is a novel 123Iodine radiolabeled PARP inhibitor (rPARPi) which will soon enter a Phase 1 clinical study in recurrent glioblastoma patients, an indication of high unmet medical need. Ariceum intends to expand the development of ATT001 into other fast growing PARP expressing tumours.

Through our partnership with UCB Pharma, we will explore new targets to develop first-in-class radiopharmaceuticals to continue expanding our pipeline beyond the two lead assets.